However, Jin Yihong, having just gone through so much trouble to reclaim her equity, was not about to dilute her shares again.
These investment firms then approached Wu Ting, hoping to invest in his company, but he flatly refused.
All of Wu Ting's research projects were progressing steadily. With a constant stream of grants and funding, plus support from the Pfizer settlement fund, he had absolutely no need for outside capital.
Moreover, contracts had been signed and a market strategy was in place for all of Wu's Pharmaceutical Company's products. Going forward, its product line and market position would only grow larger and more stable.
Wu Ting had already amassed his initial capital. All he had to do now was continue to monetize the results of his research and development.
As for Wu's Pharmaceutical Company, the parent company, Wu Ting had no intention of taking it public. He would keep everything under his own control.
